secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ventyx Biosciences, Inc. (—)
CIK:        0001851194
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001193125-24-061538
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ventyx raises $100M in private placement; discloses securities class action lawsuit
--------------------------------------------------------------------------------

- Sold 11,174,000 shares at $8.95/share for gross proceeds ~$100M; led by Farallon, Cormorant, Deerfield, Redmile, Surveyor.
- Net proceeds to fund VTX3232, VTX2735, VTX002 clinical development and preclinical programs; cash runway extended into at least 2H 2026.
- Private placement expected to close on March 11, 2024, subject to customary conditions.
- Securities class action filed Mar 1 alleges misleading statements on VTX958 Phase 2 trial; company believes lawsuit without merit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851194/000119312524061538/0001193125-24-061538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851194/000119312524061538/d765460d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-061538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer